World Health Organization 2018 survey states that globally around 422 million people suffer with diabetes and approximately 2.6 % of the global blindness is due to diabetic retinopathy. The American Academy of Ophthalmology has stated that the incidence rate of diabetic macular edema in a span of 10 years to be 20 % in younger patients and 40 % in older patients. Currently combined therapy of photocoagulation laser therapy and Anti-VEGF drugs are employed to achieve improved vision and avoid blindness. The drugs in phase III clinical trials such as conbercept, pemofibrate, ranibizumab and aflibercept intravitreal injection are tested for better drug efficacy.

Therapy segment for the diabetic macular edema treatment market majorly comprises drugs and surgery. The drugs are further sub segmented as Anti-VEGF, Corticosteroids and other drugs (Triamcinolone Acetonide and Bevacizumab). Anti-VEGF treatment adopted is Ranibizumab and Aflibercept. Corticosteroids includes dexamethasone and Fluocinolone Acetonide. The surgery segment comprises of photocoagulation laser therapy and intravitreal implants. In order to understand the current trend existing in the market the data forecast and market estimation for treatment segment is given in the scope of the report.

Competitive landscape is an assessment tool highlights the performance of the fundamental players currently engaged in the diabetic macular edema treatment market. The parameters employed are geographical presence, product portfolio and inception. Company profiles gives a brief update regarding the latest technological advancement in the photocoagulation laser therapy market and effective collaboration among niche players. The fundamental players in the diabetic macular edema treatment market are Allergan, Inc., Quantel-Medical, Alimera Sciences, Bausch and Lomb Incorporated, Carl Zeiss Meditec AG, Ellex, Genetech, Inc., IRIDEX Corporation, LUMENIS, Novartis AG, and Regeneron Pharmaceuticals, Inc.

Diabetic macular edema is a complication seen in patients suffering with diabetic retinopathy in which the blood vessels of macula region of retina are damaged and allows the fluid to escape. It is prevalent in two forms as focal diabetic macular edema which employs surgical treatment options and diffuse macular edema which is taken care by drug therapy. Photocoagulation laser therapy is utilized as a standard treatment protocol in patients suffering with blurred visions and double visions. The yellow pattern 577 nm micropulse laser is preferred to the conventional green pattern 532 wavelength due to less thermal absorption by the xanthophyll pigments. Post 2005 the anti-VEGF drug treatment has been considered as the first line of treatment for diabetic macular edema as it inhibits various isoforms of VEGF thus enhancing vision and preventing blindness. Intravitreal implants will be the trendsetter during the forecast duration 2020-2030; Retisert, Illuvien and Ozurdex will provide high drug efficacy and safety. The prominent players in diabetic macular edema treatment market are Allergan, Inc., Alimera Sciences, Bausch and Lomb Incorporated, Carl Zeiss Meditec AG, Ellex, Genetech, Inc., IRIDEX Corporation, LUMENIS, Novartis AG, Quantel-Medical and Regeneron Pharmaceuticals, Inc.

As per the research finding of Center for Disease Control and Prevention 2019, there were around 4.2 million people suffering with diabetic retinopathy with 655,000 of them suffering with diabetic retinopathy. The increasing number of U.S. citizens being diagnosed for type 2 diabetes and the recent USFDA approval for intravitreal implants such as Iluvien, Eylea and Ozurdex will contribute to the assist the growth of North American diabetic macular edema treatment market. The Western European region shows remarkable growth in the diabetic macular edema treatment market due to presence of cardinal players and prolific investment in the research and development segment to develop intravitreal implants. Asia Pacific reflects a balanced growth as a result of the competitive market created by the global and domestic manufacturers of photocoagulation lasers. In addition the supportive regulatory environment for the drug therapies and intravitreal implants have a positive impact on Asia Pacific market. Proactive role played by government healthcare agencies to promote eyecare and increasing eyesight awareness campaign conducted by major players will thrust the diabetic macular edema treatment market growth in the Middle East and Latin America.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Diabetic Macular Edema Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Diabetic Macular Edema Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Diabetic Macular Edema Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Diabetic Macular Edema Treatment market?
• Which is the largest regional market for Diabetic Macular Edema Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Diabetic Macular Edema Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Diabetic Macular Edema Treatment market worldwide?